Stull, Stull & Brody Announces Class Action
on Behalf of Shareholders of Amgen Inc.

NEW YORK, NY--(MARKET WIRE)--Apr 18, 2007 -- Notice is hereby given that a class action has been commenced in the United States District Court for the Central District of California on behalf of a class (the "Class") consisting of all persons or entities who purchased or otherwise acquired publicly traded securities of Amgen Inc. ("Amgen" or the "Company") (NasdaqGS:AMGN - News) between May 4, 2005 and March 9, 2007 (the "Class Period").
Stull, Stull & Brody has substantial experience representing employees who suffered losses from purchases of their employer's stock in their 401(k) plans. If you bought Amgen Inc.'s stock through your Amgen retirement account and have information or would like to learn more about these claims, please contact us.

The complaint charges Amgen and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Amgen, the largest biotechnology company in the world, makes and sells Epogen and Aranesp, erythropoiesis-stimulating agents, a type of drug which encourages the creation of oxygen carrying red blood cells. The Company alleges that during the Class Period, defendants marketed Aranesp and Epogen to doctors for off-label uses. As a result, Amgen sold several hundred million dollars worth of drugs each year for these off-label uses. In October 2006, a group of researchers halted a clinical study of head and neck cancer patients treated with Aranesp because more deaths occurred in patients taking Aranesp than in those taking a placebo. Defendants did not disclose these results to investors. On February 16, 2007, a publication called The Cancer Letter published an article about the results of the study and on March 9, 2007, the FDA mandated a "black box" warning regarding the off-label use of Aranesp and Epogen. These revelations caused Amgen's stock price to decline.

If you purchased Amgen's publicly traded securities during the Class Period, you may request that the Court appoint you as lead plaintiff no later than 60 days from April 17, 2007. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Stull, Stull & Brody, or other counsel of your choice, to serve as your counsel in this action. Stull, Stull & Brody has litigated many class actions for violations of securities laws in federal courts over the past 30 years and has obtained court approval of substantial settlements on numerous occasions. Stull, Stull & Brody maintains offices in both New York and Los Angeles.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Tzivia Brody, Esq. at Stull, Stull & Brody by e-mail at SSBNY@aol.com, or by fax at 212/490-2022, or by writing to Stull, Stull & Brody, 6 East 45th Street, New York, NY 10017. You can also visit our website at www.ssbny.com.

© Copyright 1999-2005. Stull, Stull & Brody
Published in U.S.A. All rights reserved.
Reproduction/redistribution prohibited.